MedPath

Alginic acid

Generic Name
Alginic acid
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
9005-32-7
Unique Ingredient Identifier
8C3Z4148WZ
Background

Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (Phacophycae) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages . Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years . Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer . It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid . Alginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years .

Indication

Indicated for the management of gastric reflux, reflux oesophagitis, hiatus hernia, heartburn (including heartburn of pregnancy) and similar gastric distress .

Associated Conditions
Dyspepsia, Flatulence, Gastro-esophageal Reflux Disease (GERD), Gastroesophageal Reflux, Heartburn, Reflux Acid, Reflux Esophagitis (RE), Regurgitation
Associated Therapies
-
pharmabiz.com
·

Norgine submits MAA to EMA for eflornithine in high-risk neuroblastoma

Norgine filed a marketing authorisation application to EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. Eflornithine, approved by FDA for HRNB, shows improved survival rates. Norgine aims to provide new treatment options, addressing the high unmet medical need in pediatric oncology.
onclive.com
·

EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma

A marketing authorization application for eflornithine (Iwilfin) to treat high-risk neuroblastoma has been submitted to the EMA. Supported by studies showing improved survival rates, this follows FDA approval in 2023. Applications were also submitted in Australia, Switzerland, and the UK in April 2024.
boerse-social.com
·

Norgine submits Marketing Authorisation Application to the European Medicines Agency for Eflornithine in High-Risk Neuroblastoma

Norgine submitted a marketing authorisation application to the EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. Eflornithine, approved by the FDA for HRNB, aims to reduce relapse risk, supported by trial data showing improved survival rates.
biospace.com
·

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine in high-risk neuroblastoma

Norgine submitted a marketing authorisation application to the EMA for eflornithine in high-risk neuroblastoma, following FDA approval. This aims to provide a new treatment option, reducing relapse risk post-standard care, highlighting Norgine's commitment to addressing unmet medical needs in pediatric oncology.

Norgine Files Marketing Authorization for Eflornithine in High-Risk Neuroblastoma

Norgine filed a marketing authorisation application to EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. This aims to provide a new treatment option in paediatric oncology. Norgine, in partnership with USWM, LLC, plans to commercialise eflornithine in Europe, Australia, and New Zealand. FDA approved eflornithine as the first oral maintenance therapy for HRNB in December 2023, based on improved survival outcomes in trials.
ots.at
·

Norgine submits Marketing Authorisation Application to the EMA for eflornithine in high-risk neuroblastoma

Norgine filed a marketing authorisation application to the EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. Eflornithine, approved by the FDA for reducing relapse risk in HRNB, shows improved survival rates. Norgine aims to provide new treatment options for pediatric oncology patients.
© Copyright 2025. All Rights Reserved by MedPath